MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.brs.2018.08.009

Медицинская библиотека · Brain stimulation · 2018

BDNF genotype and tDCS interaction in aphasia treatment.

Fridriksson Julius, Elm Jordan, Stark Brielle C, Basilakos Alexandra, Rorden Chris, Sen Souvik, George Mark S, Gottfried Michelle, Bonilha Leonardo

СтатьяРандомизированное исследованиеПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

BACKGROUND

Several studies, including a randomized controlled trial by our group, support applying anodal tDCS (A-tDCS) to the left hemisphere during behavioral aphasia treatment to improve outcomes. A clear mechanism explaining A-tDCS's efficacy has not been established, but modulation of neuroplasticity may be involved.

OBJECTIVE/HYPOTHESIS: The brain-derived neurotrophic factor (BDNF) gene influences neuroplasticity and may modulate the effects of tDCS. Utilizing data from our recently completed trial, we conducted a planned test of whether aphasia treatment outcome is influenced by interaction between A-tDCS and a single-nucleotide polymorphism of the BDNF gene, rs6265.

METHODS

Seventy-four individuals with chronic stroke-induced aphasia completed 15 language therapy sessions and were randomized to receive 1 mA A-tDCS or sham tDCS (S-tDCS) to the intact left temporoparietal region for the first 20 min of each session. BDNF genotype was available for 67 participants: 37 participants had the typical val/val genotype. The remaining 30 participants had atypical BDNF genotype (Met allele carriers). The primary outcome factor was improvement in object naming at 1 week after treatment completion. Maintenance of treatment effects was evaluated at 4 and 24 weeks.

RESULTS

An interaction was revealed between tDCS condition and genotype for treatment-related naming improvement (F = 4.97, p = 0.03). Participants with val/val genotype who received A-tDCS showed greater response to aphasia treatment than val/val participants who received S-tDCS, as well as the Met allele carriers, regardless of tDCS condition.

CONCLUSION

Individuals with the val/val BDNF genotype are more likely to benefit from A-tDCS during aphasia treatment.

Для цитирования: Fridriksson Julius, Elm Jordan, Stark Brielle C, Basilakos Alexandra, Rorden Chris, Sen Souvik, George Mark S, Gottfried Michelle, Bonilha Leonardo. BDNF genotype and tDCS interaction in aphasia treatment.. Brain stimulation. 2018. DOI: 10.1016/j.brs.2018.08.009.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.